{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:13:01Z","timestamp":1778659981161,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Current data indicate that low-dose colchicine (0.5 mg\/day) may reduce the risk of major\nadverse cardiovascular (CV) events (MACE) in patients with coronary artery disease and thus can\nbecome a new standard, effective, cost-efficient, and well-tolerated therapy for cardiac patients. Various important randomised controlled studies have reported on colchicine's influence on CV outcomes, and meta-analyses of these trials show that colchicine mitigates the risk of recurrent MACE\nby 25%, resulting in its recent approval by the Food and Drug Administration for the management\nand prevention of CV disease (CVD). While colchicine reduces MACE risk, its survival benefit remains inconclusive, warranting further long-term investigations. The non-significant decrease in CV\ndeath of ~20% is surpassed by a more apparent, borderline non-significant rise in the risk of non-CV\ndeath by ~40%. Main populations comprising patients with heart failure, patients submitted to surgical revascularisation, females, elderly persons, and non-Caucasians are under-represented in current\ntrials, limiting the generalisability of such treatment. Thus, colchicine shows promise in curtailing\nMACE, additional data from large-scale, long-term trials are needed to corroborate such findings\nbefore its widespread use in clinical practice to favourably influence the secondary prevention of\natherosclerotic CVD. Colchicine may have important advantages in curtailing myocardial infarction\nin specific high-risk patient groups but uncertainty about the magnitude of the impact on survival\nremains, particularly in the general population. Unfortunately, this agent is plagued by gastrointestinal side effects, which may deter its use. More data from larger-scale randomised studies will be\nrequired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115701611401876260416031908","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:49:01Z","timestamp":1778658541000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory\nMechanisms and Clinical Utility"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6837-1761","authenticated-orcid":true,"given":"Antonis A.","family":"Manolis","sequence":"first","affiliation":[{"name":"Department of Medicine, Elpis General Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-0984","authenticated-orcid":true,"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Aiginiteio UniversityHospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":true,"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokrateio University Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611401876260416031908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/253619\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611401876260416031908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:49:35Z","timestamp":1778658575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/253619\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611401876260416031908","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}